Who are Rescue medications for sacituzumab tirumotecan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sacituzumab Govitecan (SG), Dato-DXd, DS-1062a, Tisotumab Vedotin, LONCASTUXIMAB TESIRINE, Tivdak.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rescue-medications-for-sacituzumab-tirumotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rescue medications for sacituzumab tirumotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rescue medications for sacituzumab tirumotecan (Rescue medications for sacituzumab tirumotecan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antibody-drug conjugate. Area: Oncology.

phase 3 antibody-drug conjugate Trop-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Rescue medications for sacituzumab tirumotecan (Rescue medications for sacituzumab tirumotecan) — Merck Sharp & Dohme LLC. Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2, delivering a cytotoxic payload to cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rescue medications for sacituzumab tirumotecan TARGET	Rescue medications for sacituzumab tirumotecan	Merck Sharp & Dohme LLC	phase 3	antibody-drug conjugate	Trop-2
Sacituzumab Govitecan (SG)	Sacituzumab Govitecan (SG)	University of California, Irvine	phase 3	Antibody-drug conjugate (ADC)	Trop-2 (TACSTD2)
Dato-DXd	Dato-DXd	AstraZeneca	phase 3	Antibody-drug conjugate (ADC)	TROP-2 (Trophoblast cell surface antigen 2)
DS-1062a	DS-1062a	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	Antibody-drug conjugate (ADC)	TROP-2 (Trophoblast cell surface antigen 2)
Tisotumab Vedotin	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Tivdak	tisotumab-vedotin	SEAGEN	marketed	Antibody-drug conjugate	Tissue factor	2021-01-01

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antibody-drug conjugate class)

Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rescue medications for sacituzumab tirumotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/rescue-medications-for-sacituzumab-tirumotecan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab